|Home||» Products||» Anti Cancer Drugs - Oncology||» Biomab EGFR - Nimotuzumab 50mg INjection|
Biomab EGFR - Nimotuzumab 50mg INjection:-
BIOMAb EGFR, a humanized monoclonal antibody falls under a class of cancer treatment option known as targeted therapy.
Targeted cancer therapies interfere with cancer cell growth and division in different ways and at various points during the development, growth, and spread of cancer. They target molecules specific to cancer cells and prevent the cancerous cells from growing, dividing and spreading uncontrollably.
BIOMAb EGFR (Nimotuzumab) is also known by the brand names Theracim, Theraloc, etc., in different countries where it is approved.
BIOMAb EGFR is currently approved for treatment of head and neck cancers in India, Cuba, Argentina, Colombia, Ivory Coast, Gabon, Ukraine, Peru, Vietnam and Sri Lanka; for glioma (pediatric and adult) in Cuba, Argentina, the Philippines, Myanmar, Mexico, Indonesia, Switzerland, Vietnam, Brazil and Ukraine; for nasopharyngeal cancer (a type of head and neck cancer) in China. It has been granted orphan drug status for Glioma in the USA and for Glioma and pancreatic cancer in Europe. A number of clinical trials are being conducted worldwide to evaluate the efficacy of this molecule in various other indications also like lung cancer, pancreatic cancer, cervical cancer etc
3S CORPORATION All Rights Reserved.